Phase 1 Study of Combination Treatment with PTK 787/ZK 222584 and Cetuximab for Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics Analysis

INTRODUCTION: PTK/ZK is a small-molecule inhibitor of all three vascular endothelial growth factor (VEGF) receptors, platelet-derived growth factor receptor, colony-stimulating factor 1 receptor, and cytokine stem cell factor receptor. Cetuximab is a monoclonal antibody against epidermal growth fact...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Langenberg, Marlies HG, Witteveen, Petronella O, Lankheet, Nienke AG, Roodhart, Jeanine ML, Rosing, Hilde, van den Heuvel, Ingeborg JGM, Beijnen, Jos H, Voest, Emile E
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press Inc. 2010
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2814358/
https://ncbi.nlm.nih.gov/pubmed/20126478
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados